In the coming decade, the Italfarmaco Group proposes to consolidate its foreign business and continue the territorial expansion which began in the Nineties.

The Group's foreign turnover, which stands at some 70 million euros, now represents 32% of the total.

Numerous registrations have been obtained during the past years, enabling Italfarmaco to strengthen its commercial presence in many parts of the world; today, Italfarmaco products are sold in over 30 countries.

The company is the market leader in the field of anaemia treatment in various countries, with a product based on its own research.

Italfarmaco now has two subsidiaries in Spain and Portugal, with over 200 pharmaceutical sales representatives, and aims to obtain a direct presence on other new markets. The new subsidiary Italfarmaco Hellas will commence operations in 2001, thus furthering the territorial expansion of the group.

Italfarmaco also conducts its business in the territory of the Community of Independent States (former USSR) through its own network of representatives, which has been operational since 1997 and is expected to achieve increasing success in future years.

Italfarmaco is also strongly committed to the business of branded generics, for which its division Lifepharma S.p.A. conducts promotion and marketing activities in various Middle Eastern and North African countries.

As a result of its national and international pre-clinical, clinical, regulatory and marketing expertise, the Italfarmaco Group has entered into numerous partnerships with companies such as Bayer, Chugai, Aventis, Eli-Lilly, Janssen-Cilag, Novartis, Sanofi-Synthelabo, Schering AG, Pfizer and Yamanouchi, and is the ideal partner for new alliances and ventures in the area of Southern Europe, where it has a significant presence and competitive strength.

The group aims to expand its product range, especially in the therapeutic areas of oncology, haematology, endocrinology, hepatology, dermatology, gynaecology, neurology and the cardiovascular area, as a result of the experience, competitivity and professionalism acquired in these sectors with products of great therapeutic value.